Sinovac Announcement On H1N1 Vaccine Phase I Results Criticized
This article was originally published in PharmAsia News
Executive Summary
China's Sinovac Biotech has drawn criticism from some in the industry for promoting its H1N1 flu vaccine before it has completed the clinical trial process. They note that Hualan Biological Engineering also has a vaccine in trials, but has not made public announcements about its progress so far. One critic noted that Sinovac's announcement of Phase I results means only that it was safe for the few people in the initial trial. China has 10 vaccine producers with permission to develop a vaccine against the flu. (Click here for more